The company also exhibited its NorthStar robotic catheter, designed to work with the Magellan robotic system. The NorthStar catheter is designed to simplify and enhance catheter navigation and therapeutic intervention in the peripheral vasculature. The Magellan robotic system and NorthStar robotic catheter are CE-marked and available for sale in Europe. They are 510(k) pending and not available for sale in the United States.
“We are excited to showcase our Magellan robotic system and NorthStar robotic catheter at this foremost exhibition on endovascular therapy, and this is an important event in the initial commercial launch of our new system platform,” said Bruce Barclay, president and CEO of Hansen Medical. “Based on the initial clinical and pre-clinical work and feedback from a number of leading clinicians worldwide, these products have the potential to optimise the way physicians navigate the vasculature. The CE marked system and catheter give physicians maximum flexibility and control through independent distal tip control of a catheter and a sheath as well as through robotic manipulation of a standard guidewire from a centralised, remote workstation. Moreover, this proprietary technology has the ability to provide physicians important clinical benefits by allowing precise and predictable catheter navigation of peripheral vessels.”
The Magellan robotic system and NorthStar robotic catheter are intended to be used to facilitate navigation to anatomical targets in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices.
Last year, the company announced the completion of its first-in-man study in Europe during which 20 endovascular procedures were performed with an earlier version of the Magellan robotic system, demonstrating its potential to allow physicians to treat peripheral vascular disease, while lessening radiation exposure.